ライフサイエンスコーパス: after stopping

1 years of immunotherapy (approximately 1 year after stopping).

2 e smoking-attributed risk more than 10 years after stopping.

3 ping 1.16 [1.08-1.23], 2p=0.00001; 5-9 years after stopping 1.07 [1.02-1.13], 2p=0.009).

4 sers 1.24 [1.15-1.33], 2p<0.00001; 1-4 years after stopping 1.16 [1.08-1.23], 2p=0.00001; 5-9 years a

5 eflux disease experience symptomatic relapse after stopping acid-suppressive medication.

6 commonly occur in lung transplant recipients after stopping anti-CMV prophylaxis.

7 The unadjusted risk ratio for recurrent VTE after stopping anticoagulant therapy in patients with an

8 , and/or d-dimer testing is positive 1 month after stopping anticoagulant therapy.

9 Within 6 weeks after stopping antiretroviral therapy, each patient expe

10 biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized s

11 Two hours after stopping behavioral experiments, we euthanized rat

12 " remained free of HIV rebound over a decade after stopping cART.

13 Five relapsed after stopping CBZ treatment and were rendered euthyroid

14 ing of adverse events in the initial 90 days after stopping clopidogrel among both medically treated

15 for death or MI in the 0- to 90-day interval after stopping clopidogrel compared with the 91- to 365-

16 bound of platelet activity to above baseline after stopping clopidogrel in patients with stable coron

17 rval: [CI])/1,000 person-days of death or MI after stopping clopidogrel in the time intervals of 0 to

18 idogrel treatment, the first 90-day interval after stopping clopidogrel treatment was associated with

19 ays, and 6.5% (n = 8) during 181 to 270 days after stopping clopidogrel treatment.

20 e needed to confirm the clustering of events after stopping clopidogrel, including associations with

21 2009, followed for all-cause mortality or MI after stopping clopidogrel.

22 gs were made 'on' deep brain stimulation and after stopping deep brain stimulation for 2 days.

23 MT discontinuation; follow-up for >/=3 years after stopping DMT; not restarting DMT for >/=3 months a

24 5 daily doses, and remained >90% for 7 days after stopping drug from steady-state conditions.

25 point, sustained unresponsiveness at 4 weeks after stopping early intervention oral immunotherapy (4-

26 Within 1 year after stopping ETV therapy, "clinical relapse" (an episo

27 iral decline and appeared to prevent relapse after stopping ETV.

28 Formation of these inclusions is reversible after stopping expression of the expanded CGG RNA at an

29 cle pain and weakness persisted for 2 months after stopping fluoxetine.

30 t 85 percent of patients died within 15 days after stopping food and fluids.

31 usually die a "good" death within two weeks after stopping food and fluids.

32 so demonstrated a decline in platelet counts after stopping heparin, warfarin-associated supratherape

33 g heparin anticoagulation, and platelet fall after stopping heparin.

34 ubsequent treatment an average of 0.3 months after stopping ibrutinib with a median OS of 5.8 months

35 the period between starting use and 10 years after stopping increases with age at last use: for examp

36 Importantly, at 1 year after stopping induction therapy, response was sustained

37 R 1,500 microg, IL-4R 500 microg, or placebo after stopping inhaled corticosteroids.

38 However, after stopping lamivudine in groups 2 and 3, serum HBV D

39 (18)F(-) PET spine scans at 0, 6, and 12 mo after stopping long-term bisphosphonate treatment were u

40 ve study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide anal

41 After stopping maraviroc, they were followed for an addi

42 After stopping mechanical ventilation in the operating r

43 Progenitors continued to divide after stopping migration, generating clusters of related

44 f 24 successfully passed a challenge 1 month after stopping OIT and achieved sustained unresponsivene

45 tolerated 2000 mg of peanut protein 6 weeks after stopping omalizumab versus 1 (12%) of 8 receiving

46 e, we reported a low rate of acute rejection after stopping or markedly lowering immunosuppression.

47 months of oxygen treatment, and for 3 months after stopping oxygen.

48 drug concentrations persist for several days after stopping PrEP, a reasonable recommendation is to c

49 fect on mossy fiber sprouting was reversible after stopping rapamycin and did not directly correlate

50 The extent of IH after stopping routine caffeine treatment and the potent

51 1 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatmen

52 llenge to 4000 mg of peanut protein 12 weeks after stopping study drug.

53 all randomised patients for at least 1 year after stopping study treatment.

54 but were still significant at least 5 years after stopping tamoxifen therapy (RR per year of use, 0.

55 bined oral contraceptives and in the 5 years after stopping than women who began use at older ages, b

56 Wake-up times after stopping the drug were assessed by blinded and unb

57 After stopping the enzyme reaction, compounds were extra

58 insulin sensitivity was observed within 4 h after stopping the indinavir infusion.

59 After stopping the infliximab for infusion-related react

60 nal blood samples were obtained up to 24 hrs after stopping the infusion and analyzed for propofol co

61 verse events, the majority of which occurred after stopping the infusion.

62 6 weeks after stopping the intervention the effect waned (7.3 m

63 Effects were sustained for many years after stopping the intervention.

64 c effects appear to persist in some patients after stopping the medication.

65 midine; hypnotic response had normalized 8 d after stopping the ODNs.

66 as change in esophageal inflammation 2 weeks after stopping the PPI medication, determined by compari

67 Two weeks after stopping the PPI medication, esophageal acid expos

68 line (taking PPIs) and at 1 week and 2 weeks after stopping the PPI medication.

69 y from sedation (COMFORT score of > or = 27) after stopping the propofol infusion was rapid, averagin

70 In 13 patients who were extubated after stopping the propofol infusion, the time to extuba

71 After stopping the reaction that uses [14C]glucose 1-pho

72 zumab group had a relapse in the first month after stopping the study drug, of whom 7 had ADAMTS13 ac

73 of patients with HCV RNA <15 IU/mL 12 weeks after stopping therapy (sustained virologic response [SV

74 f patients with HCV RNA </=15 IU/mL 12 weeks after stopping therapy (sustained virologic response at

75 of patients with HCV RNA <15 IU/mL 12 weeks after stopping therapy (SVR12).

76 patients were followed for at least 48 weeks after stopping therapy and 9 underwent repeat liver biop

77 ion did not address was what would transpire after stopping therapy and whether these events would be

78 titis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamiv

79 lack of detectable HCV RNA at least 24 weeks after stopping therapy).

80 After stopping therapy, 13 of 15 patients experienced a

81 ts suffered progressive disease on study and after stopping therapy, respectively.

82 dose, a repeat DBPCFC was performed 3 months after stopping therapy.

83 s of treatment experienced virologic relapse after stopping therapy.

84 unknown whether clinical protection persists after stopping therapy.

85 seroconverters may not have durable response after stopping therapy.

86 eeks and followed for an additional 24 weeks after stopping therapy.

87 ined oral contraceptives and in the 10 years after stopping there is a small increase in the relative

88 sis demonstrated that loss of MR4.5 3 months after stopping TKI was predictive of failure to maintain

89 n the aminotransferase level were reversible after stopping tolvaptan.

90 After stopping TPA application, partial skin tumor regre

91 After stopping trastuzumab, the majority of patients who

92 was sustained virological response 12 weeks after stopping treatment (SVR12).

93 Virus rebounds after stopping treatment from the stable HBV covalently-

94 Mean (SD) follow-up after stopping treatment with clopidogrel was 196 (152)

95 idogrel treatment, the first 90-day interval after stopping treatment with clopidogrel was associated

96 rtality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel.

97 ys, and 9.7% (n = 26) during 181 to 270 days after stopping treatment with clopidogrel.

98 observation period, except for one that died after stopping treatment.

99 f failure at the end of treatment or relapse after stopping treatment.

100 increase in risk that persists for one year after stopping treatment.

101 returned to baseline dimensions about 20 min after stopping US.

102 ing breast cancer diagnosed 10 or more years after stopping use (relative risk 1.01 [0.96-1.05], NS).

103 s number of cancers diagnosed up to 10 years after stopping use is 0.5 (95 percent CI 0.3-0.7), 1.5 (

104 pretreated high-risk SKH-1 mice for 23 weeks after stopping UVB treatment decreased the number of tum

105 ther specific situations before, during, and after stopping venom immunotherapy.

106 Arrest occurred 3-27 min after stopping ventilation.